Summit Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Summit Therapeutics PLC
SMMT Stock  USD 20.13  0.66  3.17%   
Summit Therapeutics financial statements provide useful quarterly and yearly information to potential Summit Therapeutics PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Summit Therapeutics financial statements helps investors assess Summit Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Summit Therapeutics' valuation are summarized below:
Gross Profit
705 K
Market Capitalization
15.3 B
Enterprise Value Revenue
6.4 K
Earnings Share
(0.31)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental trend indicators for Summit Therapeutics PLC that can be evaluated and compared over time across competition. All traders should double-check Summit Therapeutics' current fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 13.5 B in 2025. Working Capital is likely to gain to about 49.3 M in 2025

Summit Therapeutics Total Revenue

0.0

Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 109.6 M, Interest Expense of 9.1 M or Selling General Administrative of 63.6 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 31.34. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Summit Therapeutics Correlation against competitors.

Summit Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets457.3 M435.6 M147.7 M
Slightly volatile
Total Current Liabilities43.8 M41.7 M17.4 M
Slightly volatile
Property Plant And Equipment Net7.8 M7.4 M2.2 M
Slightly volatile
Accounts Payable4.3 M4.6 M4.6 M
Pretty Stable
Cash110.1 M104.9 M61.8 M
Slightly volatile
Non Current Assets Total12.3 M11.8 M11.4 M
Slightly volatile
Cash And Short Term Investments433 M412.3 M108.3 M
Slightly volatile
Common Stock Total Equity706.2 K743.4 K3.3 M
Slightly volatile
Common Stock Shares Outstanding754.5 M718.5 M196.3 M
Slightly volatile
Liabilities And Stockholders Equity457.3 M435.6 M147.7 M
Slightly volatile
Non Current Liabilities Total4.8 M5.1 M44.4 M
Slightly volatile
Other Current Assets18.5 M11.4 M23.9 M
Slightly volatile
Other Stockholder Equity1.7 B1.6 B391 M
Slightly volatile
Total Liabilities48.9 M46.8 M61.7 M
Slightly volatile
Total Current Assets444.9 M423.8 M136.3 M
Slightly volatile
Intangible Assets7.4 M12 M8.1 M
Slightly volatile
Common Stock4.8 M7.4 M4.7 M
Pretty Stable
Net Receivables926.4 K975.2 K4.9 M
Pretty Stable
Property Plant And Equipment Gross8.9 M8.5 M2.7 M
Slightly volatile
Good Will3.4 M1.9 M2.8 M
Slightly volatile
Property Plant Equipment6.1 M5.8 M1.9 M
Slightly volatile
Other Liabilities1.2 M1.3 M6 M
Very volatile
Net Invested Capital226.3 M388.7 M115.2 M
Slightly volatile
Net Working Capital216.4 M382 M114.3 M
Slightly volatile
Capital Stock3.7 M7.4 M2.6 M
Slightly volatile

Summit Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization109.6 M104.3 M19.9 M
Slightly volatile
Interest Expense9.1 M8.7 M2.8 M
Slightly volatile
Selling General Administrative63.6 M60.5 M18.7 M
Slightly volatile
Other Operating Expenses237.6 M226.3 M63.3 M
Slightly volatile
Research Development158.3 M150.8 M48.5 M
Slightly volatile
Selling And Marketing Expenses1.6 M2.4 M2.3 M
Pretty Stable
Reconciled Depreciation84.5 K89 K967.3 K
Slightly volatile

Summit Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation84.5 K89 K844.3 K
Slightly volatile
Capital Expenditures132.1 K139 K224.3 K
Slightly volatile
Total Cash From Financing Activities400.3 M381.2 M112.4 M
Slightly volatile
End Period Cash Flow62.8 M105.2 M77.6 M
Slightly volatile
Stock Based Compensation53.5 M51 M9.8 M
Slightly volatile
Issuance Of Capital Stock501.8 M477.9 M104.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.3 K1.3 K4.1 K
Slightly volatile
Days Sales Outstanding155163762
Pretty Stable
Invested Capital58.9 M56.1 M57.8 M
Slightly volatile
Average Payables2.3 M3.9 M3.9 M
Slightly volatile
Stock Based Compensation To Revenue13.2612.633.9967
Slightly volatile
Capex To Depreciation1.561.56180.9023
Pretty Stable
EV To Sales1.5 K1.6 K4.1 K
Slightly volatile
Inventory Turnover0.00710.007556 K
Slightly volatile
Days Of Inventory On Hand41.4 K39.4 K16 K
Slightly volatile
Payables Turnover3.43.23712.2178
Slightly volatile
Sales General And Administrative To Revenue35.8334.1214.4251
Slightly volatile
Research And Ddevelopement To Revenue69.7766.4530.0639
Slightly volatile
Capex To Revenue0.861.020.3156
Slightly volatile
Cash Per Share0.440.57390.5282
Slightly volatile
Days Payables Outstanding10711323.3 K
Slightly volatile
Net Current Asset Value113.8 K128.1 K139.6 K
Slightly volatile
Tangible Asset Value49.4 M47 M48.5 M
Slightly volatile
Intangibles To Total Assets0.00410.00430.1404
Slightly volatile
Current Ratio12.010.15487.961
Very volatile
Receivables Turnover1.742.322.1234
Slightly volatile
Debt To Equity0.01760.01860.3561
Slightly volatile
Capex Per Share2.0E-42.0E-40.0036
Slightly volatile
Average Receivables7.3 M7 M3.8 M
Slightly volatile
Revenue Per Share0.00310.00330.1297
Pretty Stable
Debt To Assets0.01570.01660.0938
Slightly volatile
Graham Number1.031.161.2677
Slightly volatile
Operating Cycle41.5 K39.6 K11.3 K
Slightly volatile
Days Of Payables Outstanding10711323.3 K
Slightly volatile
Long Term Debt To Capitalization0.00840.00882.6167
Slightly volatile
Total Debt To Capitalization0.01730.01820.1007
Slightly volatile
Debt Equity Ratio0.01760.01860.3561
Slightly volatile
Quick Ratio11.5610.15487.4129
Pretty Stable
Net Income Per E B T0.760.90.9081
Pretty Stable
Cash Ratio2.392.51295.456
Slightly volatile
Days Of Inventory Outstanding41.4 K39.4 K16 K
Slightly volatile
Days Of Sales Outstanding155163762
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.211.0011.0256
Pretty Stable
Fixed Asset Turnover0.150.1625.396
Slightly volatile
Debt Ratio0.01570.01660.0938
Slightly volatile
Price Sales Ratio1.3 K1.3 K4.1 K
Slightly volatile
Asset Turnover9.0E-40.0010.1572
Slightly volatile

Summit Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.5 B12.8 B2 B
Slightly volatile
Working Capital49.3 M47 M48.5 M
Slightly volatile
Enterprise Value13.4 B12.7 B2 B
Slightly volatile

Summit Fundamental Market Drivers

Cash And Short Term Investments412.3 M

Summit Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Summit Therapeutics Financial Statements

Summit Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue16.3 M17.2 M
Cost Of Revenue15 M14.3 M
Stock Based Compensation To Revenue 12.63  13.26 
Sales General And Administrative To Revenue 34.12  35.83 
Research And Ddevelopement To Revenue 66.45  69.77 
Capex To Revenue 1.02  0.86 
Ebit Per Revenue(117.71)(111.82)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY